Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection

Transplantation

Volumn 68, Issue 5, 1999, Pages 608-616

  Woodle, E Steve ^a   Xu, Danlin ^b   Zivin, Robert A ^b   Auger, Julie ^a   Charette, Jane ^a   O'Laughlin, Rita ^a   Peace, Donna ^a   Jolliffe, Linda K ^b   Haverty, Thomas ^c   Bluestone, Jeffrey A ^a   Thistlethwaite Jr , J Richard ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

^c PRI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; METHYLPREDNISOLONE SODIUM SUCCINATE; OKT 3; OKT 3 DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TACHYCARDIA;

ACUTE DISEASE; ADULT; ANTIGENS, CD; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; RECEPTORS, FC; TREATMENT OUTCOME;

EID: 0033568236     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199909150-00003     Document Type: Article

References (19)

1. Cosimi AB, Burton RC, Colvin R, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535.
2. Thistlethwaite JR, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11: 112.
3. Van Wauwe JP, De Mey JR, Goossens JG. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 1980; 124: 2708.
4. Kung P, Goldstein G, Reinherz E, Schlossman S. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206: 347.
5. Abramowicz D, Sehandere L, Goldman M. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
6. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989; 320: 1420.
7. Hirsch R, Bluestone JA, DeNenno L, Gress RE. Anti-CD3 F(ab=)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49: 1117.
8. Woodle ES, Hussein S, Bluestone JA. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells. Transplantation 1996; 61: 798.
9. Hughes C, Wolus JA, Gianni EH, Hirsch R. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J Immunol 1994; 153: 3319.
10. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997;185: 1413.
11. Woodle ES, Thistlethwaite JR, Ghobrial IA, Jolliffe LK, Stuart FP, Bluestone JA. OKT3 F(ab=)2 fragments-retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation 1991;52: 354.
12. Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP. Bluestone, JA. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Transplantation 1991; 52 (2): 361.
13. Woodle ES, Thistlethwaite JR, Jolliffe LK, et al. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol 1992; 148(9): 2756.
14. Alegre ML, Peterson LJ, Xu D, et al. A nonactivating anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57: 1537.
15. Solez K. Axelsen RA, Benediktsson H, et al., International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993; 44(2): 411.
16. Woodle ES, Bruce DS, Josephson M, et al. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Clin Transplant 1996; 10(4): 389.
17. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80.
18. Thistlethwaite JR, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1998; 11: 112-119.
19. Smith JA, Tong Q, Bluestone JA. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998; 160: 4841.